Total Payments
$5,078
2024 Payments
$1,631
Companies
26
Transactions
239
Medicare Patients
2,280
Medicare Billing
$287,429
Payment Breakdown by Category
Food & Beverage$5,078 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,078 | 239 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,719 | 80 | $0 (2024) |
| PFIZER INC. | $541.28 | 33 | $0 (2024) |
| Celgene Corporation | $524.57 | 26 | $0 (2024) |
| GENZYME CORPORATION | $393.24 | 14 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $343.18 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $313.16 | 13 | $0 (2023) |
| Gilead Sciences, Inc. | $305.48 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $230.00 | 6 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $201.74 | 13 | $0 (2023) |
| Stryker Corporation | $68.59 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,631 | 77 | ABBVIE INC. ($627.34) |
| 2023 | $1,902 | 84 | ABBVIE INC. ($682.74) |
| 2022 | $864.05 | 39 | ABBVIE INC. ($323.98) |
| 2021 | $138.18 | 6 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($62.21) |
| 2020 | $190.91 | 11 | AbbVie Inc. ($42.00) |
| 2019 | $352.08 | 22 | Ferring Pharmaceuticals Inc. ($130.19) |
All Payment Transactions
239 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.28 | General |
| 12/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.48 | General |
| 12/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/11/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.68 | General |
| 11/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.03 | General |
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.63 | General |
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.74 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: LIVER DISEASE | ||||||
| 10/08/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/02/2024 | Stryker Corporation | NEPTUNE (Device) | Food and Beverage | In-kind items and services | $68.59 | General |
| Category: SURGICAL | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.23 | General |
| 09/24/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.62 | General |
| Category: Neuroscience | ||||||
| 09/13/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/10/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $29.67 | General |
| Category: Rare Disease | ||||||
| 08/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.39 | General |
| 08/26/2024 | ABBVIE INC. | CREON (Drug), LINZESS, VIBERZI | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 463 | 519 | $339,453 | $64,570 |
| 2022 | 15 | 598 | 683 | $401,214 | $77,076 |
| 2021 | 14 | 617 | 692 | $388,230 | $77,084 |
| 2020 | 15 | 602 | 708 | $356,460 | $68,699 |
Total Patients
2,280
Total Services
2,602
Medicare Billing
$287,429
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 102 | 127 | $41,275 | $13,574 | 32.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 60 | 60 | $87,000 | $13,486 | 15.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 66 | 69 | $70,725 | $7,741 | 10.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 55 | 55 | $55,000 | $6,840 | 12.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 27 | 27 | $19,170 | $5,059 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $18,000 | $4,872 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 69 | $20,700 | $4,606 | 22.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 35 | $11,375 | $3,526 | 31.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 14 | 14 | $9,408 | $2,728 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 16 | $4,000 | $1,072 | 26.8% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 11 | 11 | $2,800 | $1,066 | 38.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 89 | 92 | $94,300 | $10,467 | 11.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 47 | 47 | $68,150 | $10,231 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 73 | 90 | $29,250 | $9,798 | 33.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 130 | $39,000 | $9,586 | 24.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 51 | 51 | $51,000 | $7,291 | 14.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 37 | 37 | $26,270 | $7,122 | 27.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 45 | $14,625 | $3,853 | 26.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 43 | 43 | $13,545 | $3,700 | 27.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 17 | 17 | $11,424 | $3,306 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $10,000 | $2,799 | 28.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 17 | 18 | $17,100 | $2,515 | 14.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 41 | $10,250 | $2,499 | 24.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $6,600 | $1,951 | 29.6% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Office | 2022 | 17 | 17 | $5,100 | $1,411 | 27.7% |
About Dr. Mark Epstein, M.D
Dr. Mark Epstein, M.D is a Specialist healthcare provider based in Concord, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891760005.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Epstein, M.D has received a total of $5,078 in payments from pharmaceutical and medical device companies, with $1,631 received in 2024. These payments were reported across 239 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($5,078).
As a Medicare-enrolled provider, Epstein has provided services to 2,280 Medicare beneficiaries, totaling 2,602 services with total Medicare billing of $287,429. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Concord, MA
- Active Since 02/21/2006
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1891760005
Products in Payments
- RINVOQ (Biological) $761.66
- XELJANZ (Drug) $541.28
- ZEPOSIA (Drug) $484.96
- SKYRIZI (Biological) $427.77
- DUPIXENT (Biological) $393.24
- XIFAXAN (Drug) $318.79
- ENTYVIO (Biological) $272.92
- STELARA (Biological) $230.00
- CREON (Drug) $225.03
- CLENPIQ (Drug) $164.17
- LINZESS (Drug) $142.13
- VIBERZI (Drug) $77.47
- NEPTUNE (Device) $68.59
- IBSRELA (Drug) $61.87
- AVSOLA (Biological) $49.32
- REBYOTA (Biological) $37.57
- Humira (Biological) $32.14
- General - Polypectomy (Device) $29.96
- IQIRVO (Drug) $29.67
- RESMETIROM (Drug) $26.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Concord
Mark Salvaggio, M.d, M.D
Specialist — Payments: $9,126
Specialist $9,126
Anthony Aversa, M.d, M.D
Specialist — Payments: $9,086
Specialist $9,086
Dr. James Oelsen, Md, MD
Specialist — Payments: $5,597
Specialist $5,597
Carlos Andersen, M.d, M.D
Specialist — Payments: $3,343
Specialist $3,343
Frank Tzeng, M.d, M.D
Specialist — Payments: $3,241
Specialist $3,241
Peter Wilson, M.d, M.D
Specialist — Payments: $1,785
Specialist $1,785